Please login to the form below

Not currently logged in
Email:
Password:

Abbott pays $110m for investigational kidney injury drug

Assumes all rights to Action Pharma's AP214

Abbott has acquired Action Pharma's AP214, an investigational compound currently in phase II study for the prevention of acute kidney injury (AKI) associated with major cardiac surgery.

The US firm will pay Denmark-based Action $110m in an upfront payment, and assume all responsibility for funding all future development and commercialisation activities for the treatment, but the deal doesn't include any later milestone payments or royalties.

The drug demonstrated positive outcomes in phase IIb trials evaluating its efficacy, safety and tolerability, and Abbott says it plans to conduct further phase II studies later this year.

AP214 is being developed to function as a hormone analogue targeting both systemic inflammation and the death of cells caused by a lack of blood flow that occur during surgery.

This can lead to kidney injury, which has been associated with increased short- and long-term mortality and co-morbidity, as well as extended stays in hospital and permanent decline in renal function.

"Clinical experience with AP214 in cardiac surgery patients suggests that it has the potential to be the first compound specifically approved to prevent acute kidney injury, a long-standing unmet need in the medical community," said Dr John Leonard, senior VP of pharmaceutical research and development at Abbott.

He continued: "This acquisition complements and broadens Abbott's late-stage renal care pipeline and builds on our existing experience in treating kidney disease."

This pipeline includes bardoxolone and atrasentan, both of which are in development for chronic kidney disease (CKD).

Bardoxolone is being developed in partnership with Reata Pharmaceuticals, while atrasentan was discovered in-house.

4th May 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

#DemandDiversity: We’re calling on the clinical trials industry to include us all
The lack of diversity in clinical trials is something we’ve spoken about time and time again. By now, you might think we sound a bit like a broken record. But,...
Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...